Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Debt / NOTE 1.000% 8/1
-
Market price (% of par)
-
132.8%
-
Total 13F principal
-
$431,219,360
-
Principal change
-
-$221,265,100
-
Total reported market value
-
$573,250,279
-
Number of holders
-
54
-
Value change
-
-$303,578,944
-
Number of buys
-
15
-
Number of sells
-
33
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 as of Q4 2025
As of 31 Dec 2025,
HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 was held by
54 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$431,219,360
in principal (par value) of the bond.
The largest 10 bondholders included
Point72 Asset Management, L.P., LMR Partners LLP, TENOR CAPITAL MANAGEMENT Co., L.P., Alberta Investment Management Corp, Jain Global LLC, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Lombard Odier Asset Management (Europe) Ltd, Balyasny Asset Management L.P., and ABSOLUTE INVESTMENT ADVISERS, LLC.
This page lists
54
institutional bondholders reporting positions
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.